<!DOCTYPE html>
<html lang="en" class="wide wow-animation smoothscroll scrollTo">
  <head>
    <!-- Site Title-->
    <title>ASK2ME&trade; - All Syndromes Known to Man Evaluator&trade;</title>
    <meta charset="utf-8">
    <meta name="viewport" content="width=device-width, height=device-height, initial-scale=1.0, maximum-scale=1.0, user-scalable=0">
    <meta http-equiv="X-UA-Compatible" content="IE=Edge">
    <meta name="keywords" content="ask2me, Panel genetic testing, Panel genetic testing cancer calculator, Comprehensive cancer panel, Hereditary cancer panel testing, Hereditary cancer susceptibility gene, Hereditary cancers, Multigene panel test, Multigene test, Panel test, DNA testing for cancer susceptibility genes, Cancer panel, Genetic testing for cancer susceptibility">
    <link rel="icon" href="images/favicon.ico" type="image/x-icon">
	<link rel="shortcut icon" href="images/favicon.ico" type="image/x-icon">
    <!-- Stylesheets-->
    <link rel="stylesheet" type="text/css" href="//fonts.googleapis.com/css?family=Open+Sans:400,700%7CUbuntu:400,700">
    <link rel="stylesheet" href="css/show2.css">
    <link rel="stylesheet" href="css/show2printing.css">
	<script type="text/javascript" src="js/fusioncharts.js"></script>
	<script>
  (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
  (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
  m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
  })(window,document,'script','https://www.google-analytics.com/analytics.js','ga');

  ga('create', 'UA-84134316-1', 'auto');
  ga('send', 'pageview');

</script>  </head>
  <body style="padding:20px;">
    <!-- Page-->
    <div style="background-color:#fff;margin: 0 auto;width:700px;">
    <table width="700px">
    	<tr>
    		<td style="width:50%;"><img width="400px" height="50px" src="images/ask2me-logo.png" alt="ASK2ME Logo"/></td>
    		<td colspan="2" style="font-size:12px;text-align:right;width:50%;"><? echo "Created: " . date("m/d/Y") ?>&nbsp;&nbsp;<a class="noPrint" style="border:none;" href="javascript: window.print();"><img src="images/printer.png" width="24" height="24" alt="Print" /></a></td>
    	</tr>
		<tr><td>&nbsp;</td></tr>
    </table>
    <table width="700px">
		<tr><td style="font-size:24px;font-weight:600;text-align:center;">
    	<!-- Report Title Area -->
    	Cancer risk estimates for a 25 year old female with a pathogenic BRCA1 variant		</td></tr>    	
    	<tr><td>&nbsp;</td></tr>
		    	<tr><td>&nbsp;</td></tr>
	</table>
	<script type="text/javascript" src="js/fusioncharts.js"></script>

        <script type="text/javascript">
            FusionCharts.ready(function () {
                new FusionCharts({"type":"msbar2D","id":"chart.summary","width":700,"height":400,"renderAt":"chart-summary","dataFormat":"json","dataSource":{"chart":{"caption":"BRCA1 cancer risk for a 25 year old female up to age 85","baseFontColor":"#333333","baseFont":"Helvetica,Arial","baseFontSize":"13","xAxisName":"Cancer","showValues":"0","exportEnabled":"1","exportFormats":"PNG=PNG Image File|JPG=JPG Image File|PDF=PDF File","exportAtClientSide":"1","exportTargetWindow":"_blank","yAxisName":"Risk %","paletteColors":"#0000ff,#1f9c1f","bgColor":"#ffffff","showBorder":"1","showShadow":"0","showAlternateHGridColor":"0","showCanvasBorder":"0","canvasBgColor":"#ffffff","legendBorderAlpha":"0","legendShadow":"0","legendIconScale":"1.25","legendPadding":"10","interactiveLegend":"1","alignLegendWithCanvas":"1","anchorAlpha":"1","anchorImageScale":"75","showTooltip":"1","yAxisMaxValue":"100"},"categories":[{"fontSize":"11","category":[{"label":"Breast"},{"label":"Ovarian"},{"label":"Pancreatic"}]}],"dataset":[{"seriesName":"Carrier","data":[{"value":"68.57","tooltext":"Breast risk for carrier is 68.57%"},{"value":"67.76","tooltext":"Ovarian risk for carrier is 67.76%"},{"value":"4.82","tooltext":"Pancreatic risk for carrier is 4.82%"}]},{"seriesName":"Non-carrier","data":[{"value":"13.66","tooltext":"Breast risk for non-carrier is 13.66%"},{"value":"1.13","tooltext":"Ovarian risk for non-carrier is 1.13%"},{"value":"1.17","tooltext":"Pancreatic risk for non-carrier is 1.17%"}]}]}});
            });
        </script>
        <script type="text/javascript">
            FusionCharts.ready(function () {
                FusionCharts("chart.summary").render();
            });
        </script>
        <table width="700px"><tr><td>BRCA1 (Breast Cancer 1 Early Onset Protein) is a tumor suppressor gene located on chromosome17 (17q21). Pathogenic variants in BRCA1 are responsible for Hereditary Breast and Ovarian Cancer (HBOC) Syndrome, which show(s) autosomal dominant inheritance. Pathogenic variants in BRCA1 are significantly associated with the following cancers: breast (female), ovarian, pancreatic.</td></tr></table><br><table width='700px'><tr><td style='font-size:24px;font-weight:600;width:100%;'>Risk Estimates as a Summary Graph</td></tr></table><table width="700px"><tr><td id="chart-summary"><!-- Fusion Charts will render here--></td></tr><tr><td>&nbsp;</td></tr></table><table width="700px"><tr><td> There is preliminary evidence associating BRCA1 with the following cancers: leukemia, melanoma. The protein product of BRCA1 is a nuclear phosphoprotein which forms the BRCA1-associated genome surveillance complex (BASC) with other proteins and can also form a heterodimer with BARD1. BRCA1 helps regulate the cell cycle and plays a role in homologous recombination repair of double-stranded DNA breaks, transcription, recombination, and ubiquitination. Other genes with which BRCA1 interacts include: ABRAXAS1, ATM, AURKA, BAP1, BARD1, BLM, BRCA2, BRCC3, BRIP1, CCAR2, CHEK1, CHEK2, CLSPN, COBRA1, DCLRE1C, EXD2, FANCD2, LMO4, MLH1, MRE11, MSH2, MSH6, NBN, P21, PALB2, PCLAF, PMS2, RAD50, RBBP8, SMC1A, UBXN1. </td></tr></table><br><table><tr><td style='font-size: 11px;'><p><strong>Note</strong><br>Risk estimates are shown from the patient’s current age through age 85 as a set of graphs, and a set of tables to allow the user to interact with the same data multiple ways.The data supporting risk for non-carriers in tables and graphs is from SEER 18 Registries (Surveillance, Epidemiology, and End Results Program), which provides the age-specific probability of developing each cancer by gender through their DevCan software.</p></td></tr></table>
        <script type="text/javascript">
            FusionCharts.ready(function () {
                new FusionCharts({"type":"msspline","id":"chart.1","width":700,"height":350,"renderAt":"chart-1","dataFormat":"json","dataSource":{"chart":{"captionAlignment":"center","captiongPadding":"30","captionOnTop":"1","caption":"BRCA1 Breast risk for a 25 year old female up to age 85","captionFontSize":"18","alignCaptionWithCanvas":"1","baseFontColor":"#333333","baseFont":"Helvetica,Arial","baseFontSize":"13","exportEnabled":"1","exportFormats":"PNG=PNG Image File|JPG=JPG Image File|PDF=PDF File","exportAtClientSide":"1","exportTargetWindow":"_blank","exportFileName":"","xAxisName":"Age","xAxisNamePadding":"15","yAxisName":"Risk %","yAxisNamePadding":"15","showValues":"0","paletteColors":"#0000ff,#1f9c1f","bgColor":"#ffffff","showBorder":"1","showShadow":"0","showAlternateHGridColor":"0","showCanvasBorder":"0","showXAxisLine":"1","xAxisLineThickness":"1","xAxisLineColor":"#999999","canvasBgColor":"#ffffff","legendBorderAlpha":"0","legendShadow":"0","legendIconScale":"1.25","legendPadding":"10","interactiveLegend":"1","alignLegendWithCanvas":"1","anchorAlpha":"1","anchorImageScale":"75","showTooltip":"1","slantLabels":"1","lineThickness":"4","yAxisMinValue":"0","forceYAxisValueDecimals":"0","yAxisMaxValue":"100","syncAxisLimits":"1","minimizeTendency":"1"},"categories":[{"fontSize":"11","category":[{"label":"25"},{"label":"26"},{"label":"27"},{"label":"28"},{"label":"29"},{"label":"30"},{"label":"31"},{"label":"32"},{"label":"33"},{"label":"34"},{"label":"35"},{"label":"36"},{"label":"37"},{"label":"38"},{"label":"39"},{"label":"40"},{"label":"41"},{"label":"42"},{"label":"43"},{"label":"44"},{"label":"45"},{"label":"46"},{"label":"47"},{"label":"48"},{"label":"49"},{"label":"50"},{"label":"51"},{"label":"52"},{"label":"53"},{"label":"54"},{"label":"55"},{"label":"56"},{"label":"57"},{"label":"58"},{"label":"59"},{"label":"60"},{"label":"61"},{"label":"62"},{"label":"63"},{"label":"64"},{"label":"65"},{"label":"66"},{"label":"67"},{"label":"68"},{"label":"69"},{"label":"70"},{"label":"71"},{"label":"72"},{"label":"73"},{"label":"74"},{"label":"75"},{"label":"76"},{"label":"77"},{"label":"78"},{"label":"79"},{"label":"80"},{"label":"81"},{"label":"82"},{"label":"83"},{"label":"84"},{"label":"85"}]}],"dataset":[{"seriesName":"Carrier","data":[{"value":"0"},{"value":"0.25"},{"value":"0.54"},{"value":"0.89"},{"value":"1.34"},{"value":"1.91"},{"value":"2.58"},{"value":"3.33"},{"value":"4.15"},{"value":"5.11"},{"value":"6.19"},{"value":"7.37"},{"value":"8.63"},{"value":"9.97"},{"value":"11.46"},{"value":"13.09"},{"value":"14.82"},{"value":"16.64"},{"value":"18.51"},{"value":"20.44"},{"value":"22.4"},{"value":"24.38"},{"value":"26.36"},{"value":"28.33"},{"value":"30.23"},{"value":"32.07"},{"value":"33.84"},{"value":"35.54"},{"value":"37.18"},{"value":"38.77"},{"value":"40.31"},{"value":"41.79"},{"value":"43.23"},{"value":"44.61"},{"value":"45.95"},{"value":"47.25"},{"value":"48.5"},{"value":"49.7"},{"value":"50.85"},{"value":"51.95"},{"value":"53"},{"value":"53.99"},{"value":"54.93"},{"value":"55.83"},{"value":"56.67"},{"value":"57.47"},{"value":"58.26"},{"value":"59.05"},{"value":"59.84"},{"value":"60.63"},{"value":"61.41"},{"value":"62.18"},{"value":"62.95"},{"value":"63.71"},{"value":"64.46"},{"value":"65.19"},{"value":"65.91"},{"value":"66.61"},{"value":"67.29"},{"value":"67.94"},{"value":"68.57"}]},{"seriesName":"Non-carrier","dashed":"1","dashLen":"4","dashGap":"4","data":[{"value":"0"},{"value":"0.01"},{"value":"0.01"},{"value":"0.02"},{"value":"0.04"},{"value":"0.05"},{"value":"0.07"},{"value":"0.1"},{"value":"0.13"},{"value":"0.16"},{"value":"0.21"},{"value":"0.26"},{"value":"0.32"},{"value":"0.38"},{"value":"0.47"},{"value":"0.57"},{"value":"0.68"},{"value":"0.81"},{"value":"0.96"},{"value":"1.13"},{"value":"1.31"},{"value":"1.5"},{"value":"1.71"},{"value":"1.93"},{"value":"2.16"},{"value":"2.4"},{"value":"2.64"},{"value":"2.89"},{"value":"3.14"},{"value":"3.4"},{"value":"3.67"},{"value":"3.94"},{"value":"4.22"},{"value":"4.5"},{"value":"4.8"},{"value":"5.11"},{"value":"5.43"},{"value":"5.76"},{"value":"6.11"},{"value":"6.47"},{"value":"6.85"},{"value":"7.23"},{"value":"7.63"},{"value":"8.04"},{"value":"8.45"},{"value":"8.85"},{"value":"9.25"},{"value":"9.64"},{"value":"10.03"},{"value":"10.41"},{"value":"10.78"},{"value":"11.14"},{"value":"11.49"},{"value":"11.82"},{"value":"12.14"},{"value":"12.44"},{"value":"12.72"},{"value":"12.99"},{"value":"13.23"},{"value":"13.46"},{"value":"13.66"}]}]}});
            });
        </script>
        <script type="text/javascript">
            FusionCharts.ready(function () {
                FusionCharts("chart.1").render();
            });
        </script>
        
        <script type="text/javascript">
            FusionCharts.ready(function () {
                new FusionCharts({"type":"msspline","id":"chart.2","width":700,"height":350,"renderAt":"chart-2","dataFormat":"json","dataSource":{"chart":{"captionAlignment":"center","captiongPadding":"30","captionOnTop":"1","caption":"BRCA1 Ovarian risk for a 25 year old female up to age 85","captionFontSize":"18","alignCaptionWithCanvas":"1","baseFontColor":"#333333","baseFont":"Helvetica,Arial","baseFontSize":"13","exportEnabled":"1","exportFormats":"PNG=PNG Image File|JPG=JPG Image File|PDF=PDF File","exportAtClientSide":"1","exportTargetWindow":"_blank","exportFileName":"","xAxisName":"Age","xAxisNamePadding":"15","yAxisName":"Risk %","yAxisNamePadding":"15","showValues":"0","paletteColors":"#0000ff,#1f9c1f","bgColor":"#ffffff","showBorder":"1","showShadow":"0","showAlternateHGridColor":"0","showCanvasBorder":"0","showXAxisLine":"1","xAxisLineThickness":"1","xAxisLineColor":"#999999","canvasBgColor":"#ffffff","legendBorderAlpha":"0","legendShadow":"0","legendIconScale":"1.25","legendPadding":"10","interactiveLegend":"1","alignLegendWithCanvas":"1","anchorAlpha":"1","anchorImageScale":"75","showTooltip":"1","slantLabels":"1","lineThickness":"4","yAxisMinValue":"0","forceYAxisValueDecimals":"0","yAxisMaxValue":"100","syncAxisLimits":"1","minimizeTendency":"1"},"categories":[{"fontSize":"11","category":[{"label":"25"},{"label":"26"},{"label":"27"},{"label":"28"},{"label":"29"},{"label":"30"},{"label":"31"},{"label":"32"},{"label":"33"},{"label":"34"},{"label":"35"},{"label":"36"},{"label":"37"},{"label":"38"},{"label":"39"},{"label":"40"},{"label":"41"},{"label":"42"},{"label":"43"},{"label":"44"},{"label":"45"},{"label":"46"},{"label":"47"},{"label":"48"},{"label":"49"},{"label":"50"},{"label":"51"},{"label":"52"},{"label":"53"},{"label":"54"},{"label":"55"},{"label":"56"},{"label":"57"},{"label":"58"},{"label":"59"},{"label":"60"},{"label":"61"},{"label":"62"},{"label":"63"},{"label":"64"},{"label":"65"},{"label":"66"},{"label":"67"},{"label":"68"},{"label":"69"},{"label":"70"},{"label":"71"},{"label":"72"},{"label":"73"},{"label":"74"},{"label":"75"},{"label":"76"},{"label":"77"},{"label":"78"},{"label":"79"},{"label":"80"},{"label":"81"},{"label":"82"},{"label":"83"},{"label":"84"},{"label":"85"}]}],"dataset":[{"seriesName":"Carrier","data":[{"value":"0"},{"value":"0.11"},{"value":"0.23"},{"value":"0.36"},{"value":"0.49"},{"value":"0.64"},{"value":"0.8"},{"value":"0.97"},{"value":"1.16"},{"value":"1.36"},{"value":"1.59"},{"value":"1.83"},{"value":"2.09"},{"value":"2.38"},{"value":"2.71"},{"value":"3.1"},{"value":"3.54"},{"value":"4.03"},{"value":"4.57"},{"value":"5.19"},{"value":"5.89"},{"value":"6.67"},{"value":"7.53"},{"value":"8.46"},{"value":"9.47"},{"value":"10.55"},{"value":"11.7"},{"value":"12.93"},{"value":"14.21"},{"value":"15.55"},{"value":"16.94"},{"value":"18.38"},{"value":"19.86"},{"value":"21.39"},{"value":"22.98"},{"value":"24.64"},{"value":"26.36"},{"value":"28.12"},{"value":"29.91"},{"value":"31.73"},{"value":"33.56"},{"value":"35.4"},{"value":"37.23"},{"value":"39.07"},{"value":"40.91"},{"value":"42.75"},{"value":"44.58"},{"value":"46.4"},{"value":"48.21"},{"value":"50.01"},{"value":"51.79"},{"value":"53.55"},{"value":"55.28"},{"value":"56.98"},{"value":"58.65"},{"value":"60.28"},{"value":"61.87"},{"value":"63.41"},{"value":"64.92"},{"value":"66.37"},{"value":"67.76"}]},{"seriesName":"Non-carrier","dashed":"1","dashLen":"4","dashGap":"4","data":[{"value":"0"},{"value":"0"},{"value":"0"},{"value":"0.01"},{"value":"0.01"},{"value":"0.01"},{"value":"0.02"},{"value":"0.02"},{"value":"0.02"},{"value":"0.03"},{"value":"0.03"},{"value":"0.03"},{"value":"0.04"},{"value":"0.04"},{"value":"0.05"},{"value":"0.05"},{"value":"0.06"},{"value":"0.07"},{"value":"0.08"},{"value":"0.09"},{"value":"0.1"},{"value":"0.11"},{"value":"0.12"},{"value":"0.14"},{"value":"0.15"},{"value":"0.17"},{"value":"0.19"},{"value":"0.21"},{"value":"0.22"},{"value":"0.24"},{"value":"0.27"},{"value":"0.29"},{"value":"0.31"},{"value":"0.33"},{"value":"0.35"},{"value":"0.38"},{"value":"0.4"},{"value":"0.43"},{"value":"0.46"},{"value":"0.48"},{"value":"0.51"},{"value":"0.54"},{"value":"0.57"},{"value":"0.61"},{"value":"0.64"},{"value":"0.67"},{"value":"0.7"},{"value":"0.74"},{"value":"0.77"},{"value":"0.8"},{"value":"0.84"},{"value":"0.87"},{"value":"0.9"},{"value":"0.94"},{"value":"0.97"},{"value":"1"},{"value":"1.03"},{"value":"1.06"},{"value":"1.08"},{"value":"1.11"},{"value":"1.13"}]}]}});
            });
        </script>
        <script type="text/javascript">
            FusionCharts.ready(function () {
                FusionCharts("chart.2").render();
            });
        </script>
        
        <script type="text/javascript">
            FusionCharts.ready(function () {
                new FusionCharts({"type":"msspline","id":"chart.3","width":700,"height":350,"renderAt":"chart-3","dataFormat":"json","dataSource":{"chart":{"captionAlignment":"center","captiongPadding":"30","captionOnTop":"1","caption":"BRCA1 Pancreatic risk for a 25 year old female up to age 85","captionFontSize":"18","alignCaptionWithCanvas":"1","baseFontColor":"#333333","baseFont":"Helvetica,Arial","baseFontSize":"13","exportEnabled":"1","exportFormats":"PNG=PNG Image File|JPG=JPG Image File|PDF=PDF File","exportAtClientSide":"1","exportTargetWindow":"_blank","exportFileName":"","xAxisName":"Age","xAxisNamePadding":"15","yAxisName":"Risk %","yAxisNamePadding":"15","showValues":"0","paletteColors":"#0000ff,#1f9c1f","bgColor":"#ffffff","showBorder":"1","showShadow":"0","showAlternateHGridColor":"0","showCanvasBorder":"0","showXAxisLine":"1","xAxisLineThickness":"1","xAxisLineColor":"#999999","canvasBgColor":"#ffffff","legendBorderAlpha":"0","legendShadow":"0","legendIconScale":"1.25","legendPadding":"10","interactiveLegend":"1","alignLegendWithCanvas":"1","anchorAlpha":"1","anchorImageScale":"75","showTooltip":"1","slantLabels":"1","lineThickness":"4","yAxisMinValue":"0","forceYAxisValueDecimals":"0","yAxisMaxValue":"100","syncAxisLimits":"1","minimizeTendency":"1"},"categories":[{"fontSize":"11","category":[{"label":"25"},{"label":"26"},{"label":"27"},{"label":"28"},{"label":"29"},{"label":"30"},{"label":"31"},{"label":"32"},{"label":"33"},{"label":"34"},{"label":"35"},{"label":"36"},{"label":"37"},{"label":"38"},{"label":"39"},{"label":"40"},{"label":"41"},{"label":"42"},{"label":"43"},{"label":"44"},{"label":"45"},{"label":"46"},{"label":"47"},{"label":"48"},{"label":"49"},{"label":"50"},{"label":"51"},{"label":"52"},{"label":"53"},{"label":"54"},{"label":"55"},{"label":"56"},{"label":"57"},{"label":"58"},{"label":"59"},{"label":"60"},{"label":"61"},{"label":"62"},{"label":"63"},{"label":"64"},{"label":"65"},{"label":"66"},{"label":"67"},{"label":"68"},{"label":"69"},{"label":"70"},{"label":"71"},{"label":"72"},{"label":"73"},{"label":"74"},{"label":"75"},{"label":"76"},{"label":"77"},{"label":"78"},{"label":"79"},{"label":"80"},{"label":"81"},{"label":"82"},{"label":"83"},{"label":"84"},{"label":"85"}]}],"dataset":[{"seriesName":"Carrier","data":[{"value":"0"},{"value":"0"},{"value":"0"},{"value":"0"},{"value":"0"},{"value":"0.01"},{"value":"0.01"},{"value":"0.01"},{"value":"0.01"},{"value":"0.01"},{"value":"0.02"},{"value":"0.02"},{"value":"0.02"},{"value":"0.03"},{"value":"0.03"},{"value":"0.04"},{"value":"0.05"},{"value":"0.06"},{"value":"0.07"},{"value":"0.08"},{"value":"0.09"},{"value":"0.11"},{"value":"0.12"},{"value":"0.14"},{"value":"0.16"},{"value":"0.19"},{"value":"0.22"},{"value":"0.25"},{"value":"0.28"},{"value":"0.32"},{"value":"0.37"},{"value":"0.42"},{"value":"0.47"},{"value":"0.53"},{"value":"0.6"},{"value":"0.67"},{"value":"0.75"},{"value":"0.84"},{"value":"0.93"},{"value":"1.04"},{"value":"1.15"},{"value":"1.27"},{"value":"1.4"},{"value":"1.54"},{"value":"1.69"},{"value":"1.84"},{"value":"2.01"},{"value":"2.18"},{"value":"2.35"},{"value":"2.54"},{"value":"2.73"},{"value":"2.93"},{"value":"3.14"},{"value":"3.35"},{"value":"3.56"},{"value":"3.77"},{"value":"3.99"},{"value":"4.2"},{"value":"4.42"},{"value":"4.62"},{"value":"4.82"}]},{"seriesName":"Non-carrier","dashed":"1","dashLen":"4","dashGap":"4","data":[{"value":"0"},{"value":"0"},{"value":"0"},{"value":"0"},{"value":"0"},{"value":"0"},{"value":"0"},{"value":"0"},{"value":"0"},{"value":"0"},{"value":"0"},{"value":"0"},{"value":"0.01"},{"value":"0.01"},{"value":"0.01"},{"value":"0.01"},{"value":"0.01"},{"value":"0.01"},{"value":"0.02"},{"value":"0.02"},{"value":"0.02"},{"value":"0.03"},{"value":"0.03"},{"value":"0.03"},{"value":"0.04"},{"value":"0.05"},{"value":"0.05"},{"value":"0.06"},{"value":"0.07"},{"value":"0.08"},{"value":"0.09"},{"value":"0.1"},{"value":"0.11"},{"value":"0.13"},{"value":"0.15"},{"value":"0.16"},{"value":"0.18"},{"value":"0.2"},{"value":"0.23"},{"value":"0.25"},{"value":"0.28"},{"value":"0.31"},{"value":"0.34"},{"value":"0.37"},{"value":"0.41"},{"value":"0.45"},{"value":"0.49"},{"value":"0.53"},{"value":"0.57"},{"value":"0.62"},{"value":"0.66"},{"value":"0.71"},{"value":"0.76"},{"value":"0.81"},{"value":"0.87"},{"value":"0.92"},{"value":"0.97"},{"value":"1.02"},{"value":"1.07"},{"value":"1.13"},{"value":"1.17"}]}]}});
            });
        </script>
        <script type="text/javascript">
            FusionCharts.ready(function () {
                FusionCharts("chart.3").render();
            });
        </script>
        <table width='700px'><tr><td style='font-size:24px;font-weight:600;width:100%;'>Risk Estimates as Graphs</td></tr><tr><td style='font-size:12px;'><p>Risk estimates are reasonable approximations based on the references cited. Use your clinical judgment to confirm the best estimate for your patient. The risk estimates can be found in table format at the end of this report.</p></td></tr></table><p class='noScreen' style='font-size:9pt;font-style:italic;padding-top:20px;page-break-after:left;'>Continued on the next page</p><table width="700px"><tr><td id="chart-1"><!-- Fusion Charts will render here--></td></tr><tr style='padding-top:20px;'><td style='height:20px;'>&nbsp;</td></tr><tr><td style='font-size:12px;width:100%;'><img src="images/5stars.png" width="100" height="30">&nbsp;Robust meta-analysis.<a target='_blank' href='https://www.ncbi.nlm.nih.gov/pubmed/17416853'><u>Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J. Clin. Oncol. 2007;25(11):1329-33.</u></a><br><br>Gene Cancer Association Ranking: 5</td></tr><tr><td>&nbsp;</td></tr></table><table width="700px"><tr><td id="chart-2"><!-- Fusion Charts will render here--></td></tr><tr style='padding-top:20px;'><td style='height:20px;'>&nbsp;</td></tr><tr><td style='font-size:12px;width:100%;'><img src="images/5stars.png" width="100" height="30">&nbsp;Robust meta-analysis.<a target='_blank' href='https://www.ncbi.nlm.nih.gov/pubmed/17416853'><u>Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J. Clin. Oncol. 2007;25(11):1329-33.</u></a><br><br>Gene Cancer Association Ranking: 5</td></tr><tr><td>&nbsp;</td></tr></table><table width="700px"><tr><td id="chart-3"><!-- Fusion Charts will render here--></td></tr><tr style='padding-top:20px;'><td style='height:20px;'>&nbsp;</td></tr><tr><td style='font-size:12px;width:100%;'><img src="images/4stars.png" width="100" height="30">&nbsp;Carrier sample size greater than 199 and paper is not a meta-analysis. <a target='_blank' href='https://www.ncbi.nlm.nih.gov/pubmed/23456555'><u>Mocci E, Milne RL, MÃ©ndez-Villamil EY, Hopper JL, John EM, Andrulis IL, Chung WK, Daly M, Buys SS, Malats N, Goldgar DE. Risk of pancreatic cancer in breast cancer families from the breast cancer family registry. Cancer Epidemiol. Biomarkers Prev. 2013;22(5):803-11.</u></a><br><br>Gene Cancer Association Ranking: 3</td></tr><tr><td>&nbsp;</td></tr></table>	<table width="700px" style="page-break-after:left;page-break-before:left;"><tr><td style="font-size:24px;font-weight:600;">Management</td></tr><tr><td style="font-size:12px;">Management options and guidelines have been published by 4 groups. This table shows the management suggestions from these groups. We only reproduce here the guidelines as published. We are not making management recommendations. We suggest you use your clinical judgment and your knowledge of the patient in determining the best management strategy.</td></tr><tr><td>&nbsp;</td></tr><tr><td><table width='100%' class='doBorderTable'><tr><th width='20%' class='doBorderHeader'>Intervention</th><th width='20%' class='doBorderHeader'>NCCN</th><th width='20%' class='doBorderHeader'>Esmo</th><th width='20%' class='doBorderHeader'>Tung</th><th width='20%' class='doBorderHeader'>Graffeo</th><tr class='doBorderRow'><td colspan='5' class='doBorderCellHeader'>Breast</td></tr><tr class='doBorderRow'><td class='doBorderCell'>Chemoprevention</td><td class='doBorderCell'>Consider risk reductions agents as options</td><td class='doBorderCell'>Consider tamoxifen</td><td class='doBorderCell'>NA</td><td class='doBorderCell'>No adequate data to support use</td></tr><tr class='doBorderRow'><td class='doBorderCell'>Clinical Breast Examination</td><td class='doBorderCell'>Start at 25. Repeat q 6- 12 months</td><td class='doBorderCell'>Start at 25 or 10y before youngest case in family. Repeat q 6-12 months</td><td class='doBorderCell'>NA</td><td class='doBorderCell'>Start at 25. Repeat q 6- 12 months</td></tr><tr class='doBorderRow'><td class='doBorderCell'>Mammogram</td><td class='doBorderCell'>Start at 30 (20-29 only if MRI not available or family history of breast cancer). Repeat annually with consideration of tomosynthesis.</td><td class='doBorderCell'>Start at 30. Repeat annually.</td><td class='doBorderCell'>NA</td><td class='doBorderCell'>Start at 30. Repeat annually alternating MRI q6 months.</td></tr><tr class='doBorderRow'><td class='doBorderCell'>MRI</td><td class='doBorderCell'>Start at 25. Repeat annually.</td><td class='doBorderCell'>Start at 25, annually.</td><td class='doBorderCell'>NA</td><td class='doBorderCell'>Start at 25. Repeat annually.</td></tr><tr class='doBorderRow'><td class='doBorderCell'>Ultrasound</td><td class='doBorderCell'>NA</td><td class='doBorderCell'>Consider if MRI is not available. May also be used as an adjunct to mammography</td><td class='doBorderCell'>NA</td><td class='doBorderCell'>NA</td></tr><tr class='doBorderRow'><td class='doBorderCell'>Risk-Reducing Mastectomy</td><td class='doBorderCell'>Consider. Discuss degree of protection, reconstruction options and potential risks</td><td class='doBorderCell'>Consider</td><td class='doBorderCell'>NA</td><td class='doBorderCell'>Consider</td></tr><tr class='doBorderRow'><td class='doBorderCell'>Self Examination</td><td class='doBorderCell'>Start at 18</td><td class='doBorderCell'>NA</td><td class='doBorderCell'>NA</td><td class='doBorderCell'>Start at 18. Repeat monthly</td></tr><tr class='doBorderRow'><td colspan='5' class='doBorderCellHeader'>Eye</td></tr><tr class='doBorderRow'><td class='doBorderCell'>Clinical Eye Exam</td><td class='doBorderCell'>Consider (ASK2Me comment: The risk of melanoma with BRCA1 is rare so unclear if this recommendation is appropriate)</td><td class='doBorderCell'>NA</td><td class='doBorderCell'>NA</td><td class='doBorderCell'>NA</td></tr><tr class='doBorderRow'><td colspan='5' class='doBorderCellHeader'>General</td></tr><tr class='doBorderRow'><td class='doBorderCell'>Genetic Testing</td><td class='doBorderCell'>Advise patient to advise at risk relatives to consider testing</td><td class='doBorderCell'>NA</td><td class='doBorderCell'>NA</td><td class='doBorderCell'>NA</td></tr><tr class='doBorderRow'><td colspan='5' class='doBorderCellHeader'>Ovary</td></tr><tr class='doBorderRow'><td class='doBorderCell'>Risk-Reducing Salpingo-Oophorectomy</td><td class='doBorderCell'>Recommend between 35- 40 and upon completion of childbearing</td><td class='doBorderCell'>Consider at 35- 40</td><td class='doBorderCell'>Consider at 35- 40</td><td class='doBorderCell'>Consider at 35- 40 and upon completion of childbearing</td></tr><tr class='doBorderRow'><td class='doBorderCell'>CA- 125</td><td class='doBorderCell'>Not sufficiently sensitive or specific but can be considered starting at 30- 35 (Combined with TVUS), if there is no RRSO</td><td class='doBorderCell'>Consider at 30. Repeat q6 months and in combination with TVUS</td><td class='doBorderCell'>NA</td><td class='doBorderCell'>TVUS and CA-125 are ovarian screening test which are not recommended, but may be considered starting at age 30-35</td></tr><tr class='doBorderRow'><td class='doBorderCell'>Transvaginal ultrasound (TVUS)</td><td class='doBorderCell'>Not sufficiently sensitive or specific but can be considered starting at 30- 35(Combined with CA-125), if there is no RRSO</td><td class='doBorderCell'>Consider at 30. Repeat q6 months and in combination with CA-125</td><td class='doBorderCell'>NA</td><td class='doBorderCell'>TVUS and CA-125 are ovarian screening test which are not recommended, but may be considered starting at age 30-35</td></tr><tr class='doBorderRow'><td class='doBorderCell'>Chemoprevention</td><td class='doBorderCell'>Consider the use of oral contraceptives</td><td class='doBorderCell'>Consider the use of oral contraceptives</td><td class='doBorderCell'>NA</td><td class='doBorderCell'>NA</td></tr><tr class='doBorderRow'><td colspan='5' class='doBorderCellHeader'>Pancreas</td></tr><tr class='doBorderRow'><td class='doBorderCell'>EUS or MR-MRCP (Endoscopic ultrasound versus magnetic resonance cholangiopancreatography)</td><td class='doBorderCell'>Consider investigational protocols (Note from  Ask2Me:  The risk of pancreas cancer with BRCA1 is rare so unclear if this recommendation is appropriate)</td><td class='doBorderCell'>NA</td><td class='doBorderCell'>NA</td><td class='doBorderCell'>NA</td></tr><tr class='doBorderRow'><td colspan='5' class='doBorderCellHeader'>Reproductive System</td></tr><tr class='doBorderRow'><td class='doBorderCell'>Pre-implantation Genetic Diagnosis</td><td class='doBorderCell'>Start at reproductive age. Advise about options</td><td class='doBorderCell'>Start at reproductive age. Advise about options</td><td class='doBorderCell'>NA</td><td class='doBorderCell'>NA</td></tr><tr class='doBorderRow'><td class='doBorderCell'>Prenatal Diagnosis</td><td class='doBorderCell'>Start at reproductive age. Advise about options</td><td class='doBorderCell'>Start at reproductive age. Advise about options</td><td class='doBorderCell'>NA</td><td class='doBorderCell'>NA</td></tr><tr class='doBorderRow'><td class='doBorderCell'>Genetic Testing</td><td class='doBorderCell'>Start at reproductive age. Consider genetic testing of a partner of a mutation carrier to inform reproductive decision making*</td><td class='doBorderCell'>NA</td><td class='doBorderCell'>NA</td><td class='doBorderCell'>NA</td></tr><tr class='doBorderRow'><td colspan='5' class='doBorderCellHeader'>Skin</td></tr><tr class='doBorderRow'><td class='doBorderCell'>Dermatological Exam</td><td class='doBorderCell'>Consider (ASK2Me comment: The risk of melanoma with BRCA1 is rare so unclear if this recommendation is appropriate)</td><td class='doBorderCell'>NA</td><td class='doBorderCell'>NA</td><td class='doBorderCell'>NA</td></tr></table></td></tr><tr><td>&nbsp;</td></tr></table><p style='font-size:10px;'>*Biallelic mutations may be associated with rare autosomal recessive conditions. Thus, consideration would be given to carrier testing the partner for mutations in the same gene if it would inform reproductive assessment and management.</p>	<table width="700px">
<tr><td style="font-size:16px;font-weight:600;">Management Recommendations</td></tr>
<tr><td>
<br>
<table class="noPrint" width="700px">
<tr><td style="font-size:12px;"><a target="_blank" href="https://www.ncbi.nlm.nih.gov/pubmed/?term=time+to+incorporate+germlike+multigene"><u>Graffeo R, Livraghi L, Pagani O, Goldhirsch A, Partridge AH, Garber JE. Time to incorporate germline multigene panel testing into breast and ovarian cancer patient care. Breast Cancer Research and Treatment. 2016 Dec;160(3):393-410</u></a>.</td></tr>
<tr><td style="font-size:12px;">&nbsp;</td></tr>
<tr><td style="font-size:12px;"><a target="_blank" href="https://www.ncbi.nlm.nih.gov/pubmed/27296296"><u>Tung N, Domchek SM, Stadler Z, Nathanson KL, Couch F, Garber JE, Robson  ME. Counselling framework for moderate-penetrance cancer-susceptibility mutations. Nature Reviews Clinical Oncology. 2016 Sep;13(9):581-8</u></a>.</td></tr>
<tr><td style="font-size:12px;">&nbsp;</td></tr>
<tr><td style="font-size:12px;"><a target="_blank" href="https://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf"><u>National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology:Breast and Ovarian</u></a>.</td></tr>
<tr><td style="font-size:12px;">&nbsp;</td></tr>
<tr><td style="font-size:12px;"><a target="_blank" href="https://www.nccn.org/professionals/physician_gls/pdf/genetics_colon.pdf"><u>National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: Colorectal</u></a>.</td></tr>
<tr><td style="font-size:12px;">&nbsp;</td></tr>
<tr><td style="font-size:12px;"><a target="_blank" href="http://annonc.oxfordjournals.org/content/27/suppl_5/v103.full.pdf+html"><u>Paluch SS, Cardoso F, Sessa C, Balmana J, Cardoso MJ, Gilbert F, Senkus E. Prevention and screening in BRCA mutation carriers and other breast/ovarian hereditary cancer syndromes: ESMO Clinical Practice Guidelines for cancer prevention and screening. Annals of Oncology. 2016; 27(5), 103-110</u></a>.</td></tr>
</table>
<table class="noScreen" width="700px">
<tr><td style="font-size:12px;">Graffeo R, Livraghi L, Pagani O, Goldhirsch A, Partridge AH, Garber JE. Time to incorporate germline multigene panel testing into breast and ovarian cancer patient care. Breast Cancer Research and Treatment. 2016 Dec;160(3):393-410.</td></tr>
<tr><td style="font-size:12px;">&nbsp;</td></tr>
<tr><td style="font-size:12px;">Tung N, Domchek SM, Stadler Z, Nathanson KL, Couch F, Garber JE, Robson  ME. Counselling framework for moderate-penetrance cancer-susceptibility mutations. Nature Reviews Clinical Oncology. 2016 Sep;13(9):581-8.</td></tr>
<tr><td style="font-size:12px;">&nbsp;</td></tr>
<tr><td style="font-size:12px;">National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology:Breast and Ovarian.</td></tr>
<tr><td style="font-size:12px;">&nbsp;</td></tr>
<tr><td style="font-size:12px;">National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology:Colorectal.</td></tr>
<tr><td style="font-size:12px;">&nbsp;</td></tr>
<tr><td style="font-size:12px;">Paluch SS, Cardoso F, Sessa C, Balmana J, Cardoso MJ, Gilbert F, Senkus E. Prevention and screening in BRCA mutation carriers and other breast/ovarian hereditary cancer syndromes: ESMO Clinical Practice Guidelines for cancer prevention and screening. Annals of Oncology. 2016; 27(5), 103-110.</td></tr>
</table>
</td></tr>
<tr><td>&nbsp;</td></tr>
</table>	<table width="700px" style="page-break-after:left;"><tr><td style="font-size:24px;font-weight:600;">Detail Risk Estimates as a Table</td></tr><tr><td style="font-size:12px;">The risk estimates have the same sources as the detail graphs earlier in this document. Risk estimates are reasonable approximations based on the references cited. User your clinical judgment to confirm the best estimate for your patient.</td></tr><tr><td>&nbsp;</td></tr><tr><td><center><p style='font-size:16px;font-weight:800;text-align:center;'>BRCA1 Breast risk for a 25 year old female up to age 85</p><table style='width:600px;' cellpadding='4' class='doBorderTable'><tr class='doBorderRow'><th class='doBorderHeader' style='text-align:center;width:10%;'>Age</th><th class='doBorderHeader' style='text-align:center;width:45%;'>Carrier %</th><th class='doBorderHeader' style='text-align:center;width:45%;'>Non-carrier %</th></tr><tr class='doBorderRow' align='right'><td class='doBorderCell' style='text-align:center;'>30</td><td class='doBorderCell' style='text-align:center;'>1.91</td><td class='doBorderCell' style='text-align:center;'>0.05</td></tr><tr class='doBorderRow' align='right'><td class='doBorderCell' style='text-align:center;'>35</td><td class='doBorderCell' style='text-align:center;'>6.19</td><td class='doBorderCell' style='text-align:center;'>0.21</td></tr><tr class='doBorderRow' align='right'><td class='doBorderCell' style='text-align:center;'>40</td><td class='doBorderCell' style='text-align:center;'>13.09</td><td class='doBorderCell' style='text-align:center;'>0.57</td></tr><tr class='doBorderRow' align='right'><td class='doBorderCell' style='text-align:center;'>45</td><td class='doBorderCell' style='text-align:center;'>22.4</td><td class='doBorderCell' style='text-align:center;'>1.31</td></tr><tr class='doBorderRow' align='right'><td class='doBorderCell' style='text-align:center;'>50</td><td class='doBorderCell' style='text-align:center;'>32.07</td><td class='doBorderCell' style='text-align:center;'>2.4</td></tr><tr class='doBorderRow' align='right'><td class='doBorderCell' style='text-align:center;'>55</td><td class='doBorderCell' style='text-align:center;'>40.31</td><td class='doBorderCell' style='text-align:center;'>3.67</td></tr><tr class='doBorderRow' align='right'><td class='doBorderCell' style='text-align:center;'>60</td><td class='doBorderCell' style='text-align:center;'>47.25</td><td class='doBorderCell' style='text-align:center;'>5.11</td></tr><tr class='doBorderRow' align='right'><td class='doBorderCell' style='text-align:center;'>65</td><td class='doBorderCell' style='text-align:center;'>53</td><td class='doBorderCell' style='text-align:center;'>6.85</td></tr><tr class='doBorderRow' align='right'><td class='doBorderCell' style='text-align:center;'>70</td><td class='doBorderCell' style='text-align:center;'>57.47</td><td class='doBorderCell' style='text-align:center;'>8.85</td></tr><tr class='doBorderRow' align='right'><td class='doBorderCell' style='text-align:center;'>75</td><td class='doBorderCell' style='text-align:center;'>61.41</td><td class='doBorderCell' style='text-align:center;'>10.78</td></tr><tr class='doBorderRow' align='right'><td class='doBorderCell' style='text-align:center;'>80</td><td class='doBorderCell' style='text-align:center;'>65.19</td><td class='doBorderCell' style='text-align:center;'>12.44</td></tr><tr class='doBorderRow' align='right'><td class='doBorderCell' style='text-align:center;'>85</td><td class='doBorderCell' style='text-align:center;'>68.57</td><td class='doBorderCell' style='text-align:center;'>13.66</td></tr></table><p class='noScreen' style='font-size:9pt;font-style:italic;page-break-after:auto;text-align:left;'>&nbsp;</p><p style='font-size:16px;font-weight:800;text-align:center;'>BRCA1 Ovarian risk for a 25 year old female up to age 85</p><table style='width:600px;' cellpadding='4' class='doBorderTable'><tr class='doBorderRow'><th class='doBorderHeader' style='text-align:center;width:10%;'>Age</th><th class='doBorderHeader' style='text-align:center;width:45%;'>Carrier %</th><th class='doBorderHeader' style='text-align:center;width:45%;'>Non-carrier %</th></tr><tr class='doBorderRow' align='right'><td class='doBorderCell' style='text-align:center;'>30</td><td class='doBorderCell' style='text-align:center;'>0.64</td><td class='doBorderCell' style='text-align:center;'>0.01</td></tr><tr class='doBorderRow' align='right'><td class='doBorderCell' style='text-align:center;'>35</td><td class='doBorderCell' style='text-align:center;'>1.59</td><td class='doBorderCell' style='text-align:center;'>0.03</td></tr><tr class='doBorderRow' align='right'><td class='doBorderCell' style='text-align:center;'>40</td><td class='doBorderCell' style='text-align:center;'>3.1</td><td class='doBorderCell' style='text-align:center;'>0.05</td></tr><tr class='doBorderRow' align='right'><td class='doBorderCell' style='text-align:center;'>45</td><td class='doBorderCell' style='text-align:center;'>5.89</td><td class='doBorderCell' style='text-align:center;'>0.1</td></tr><tr class='doBorderRow' align='right'><td class='doBorderCell' style='text-align:center;'>50</td><td class='doBorderCell' style='text-align:center;'>10.55</td><td class='doBorderCell' style='text-align:center;'>0.17</td></tr><tr class='doBorderRow' align='right'><td class='doBorderCell' style='text-align:center;'>55</td><td class='doBorderCell' style='text-align:center;'>16.94</td><td class='doBorderCell' style='text-align:center;'>0.27</td></tr><tr class='doBorderRow' align='right'><td class='doBorderCell' style='text-align:center;'>60</td><td class='doBorderCell' style='text-align:center;'>24.64</td><td class='doBorderCell' style='text-align:center;'>0.38</td></tr><tr class='doBorderRow' align='right'><td class='doBorderCell' style='text-align:center;'>65</td><td class='doBorderCell' style='text-align:center;'>33.56</td><td class='doBorderCell' style='text-align:center;'>0.51</td></tr><tr class='doBorderRow' align='right'><td class='doBorderCell' style='text-align:center;'>70</td><td class='doBorderCell' style='text-align:center;'>42.75</td><td class='doBorderCell' style='text-align:center;'>0.67</td></tr><tr class='doBorderRow' align='right'><td class='doBorderCell' style='text-align:center;'>75</td><td class='doBorderCell' style='text-align:center;'>51.79</td><td class='doBorderCell' style='text-align:center;'>0.84</td></tr><tr class='doBorderRow' align='right'><td class='doBorderCell' style='text-align:center;'>80</td><td class='doBorderCell' style='text-align:center;'>60.28</td><td class='doBorderCell' style='text-align:center;'>1</td></tr><tr class='doBorderRow' align='right'><td class='doBorderCell' style='text-align:center;'>85</td><td class='doBorderCell' style='text-align:center;'>67.76</td><td class='doBorderCell' style='text-align:center;'>1.13</td></tr></table><p style='font-size:16px;font-weight:800;text-align:center;'>BRCA1 Pancreatic risk for a 25 year old female up to age 85</p><table style='width:600px;' cellpadding='4' class='doBorderTable'><tr class='doBorderRow'><th class='doBorderHeader' style='text-align:center;width:10%;'>Age</th><th class='doBorderHeader' style='text-align:center;width:45%;'>Carrier %</th><th class='doBorderHeader' style='text-align:center;width:45%;'>Non-carrier %</th></tr><tr class='doBorderRow' align='right'><td class='doBorderCell' style='text-align:center;'>30</td><td class='doBorderCell' style='text-align:center;'>0.01</td><td class='doBorderCell' style='text-align:center;'>0</td></tr><tr class='doBorderRow' align='right'><td class='doBorderCell' style='text-align:center;'>35</td><td class='doBorderCell' style='text-align:center;'>0.02</td><td class='doBorderCell' style='text-align:center;'>0</td></tr><tr class='doBorderRow' align='right'><td class='doBorderCell' style='text-align:center;'>40</td><td class='doBorderCell' style='text-align:center;'>0.04</td><td class='doBorderCell' style='text-align:center;'>0.01</td></tr><tr class='doBorderRow' align='right'><td class='doBorderCell' style='text-align:center;'>45</td><td class='doBorderCell' style='text-align:center;'>0.09</td><td class='doBorderCell' style='text-align:center;'>0.02</td></tr><tr class='doBorderRow' align='right'><td class='doBorderCell' style='text-align:center;'>50</td><td class='doBorderCell' style='text-align:center;'>0.19</td><td class='doBorderCell' style='text-align:center;'>0.05</td></tr><tr class='doBorderRow' align='right'><td class='doBorderCell' style='text-align:center;'>55</td><td class='doBorderCell' style='text-align:center;'>0.37</td><td class='doBorderCell' style='text-align:center;'>0.09</td></tr><tr class='doBorderRow' align='right'><td class='doBorderCell' style='text-align:center;'>60</td><td class='doBorderCell' style='text-align:center;'>0.67</td><td class='doBorderCell' style='text-align:center;'>0.16</td></tr><tr class='doBorderRow' align='right'><td class='doBorderCell' style='text-align:center;'>65</td><td class='doBorderCell' style='text-align:center;'>1.15</td><td class='doBorderCell' style='text-align:center;'>0.28</td></tr><tr class='doBorderRow' align='right'><td class='doBorderCell' style='text-align:center;'>70</td><td class='doBorderCell' style='text-align:center;'>1.84</td><td class='doBorderCell' style='text-align:center;'>0.45</td></tr><tr class='doBorderRow' align='right'><td class='doBorderCell' style='text-align:center;'>75</td><td class='doBorderCell' style='text-align:center;'>2.73</td><td class='doBorderCell' style='text-align:center;'>0.66</td></tr><tr class='doBorderRow' align='right'><td class='doBorderCell' style='text-align:center;'>80</td><td class='doBorderCell' style='text-align:center;'>3.77</td><td class='doBorderCell' style='text-align:center;'>0.92</td></tr><tr class='doBorderRow' align='right'><td class='doBorderCell' style='text-align:center;'>85</td><td class='doBorderCell' style='text-align:center;'>4.82</td><td class='doBorderCell' style='text-align:center;'>1.17</td></tr></table><p class='noScreen' style='font-size:9pt;font-style:italic;page-break-after:auto;text-align:left;'>&nbsp;</p></center></td></tr><tr><td>&nbsp;</td></tr></table>	<table width="700px" style="page-break-after:left;"><tr><td style="font-size:24px;font-weight:600;">Bibliography for  BRCA1</td></tr><tr><td><p style='font-size:16px;font-weight:600;'>Breast</p><table width='700px' class='noPrint'><tr><td valign='top' style='font-size:12px;width:75%;'><a href='https://www.ncbi.nlm.nih.gov/pubmed/17416853'><u>Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J. Clin. Oncol. 2007;25(11):1329-33.</u><br><br></td><td valign='top' style='width:25%;'><img src="images/5stars.png" width="100" height="30"><br><br></td></tr></table><table width='700px' class='noScreen'><tr><td valign='top' style='font-size:12px;width:75%;'>Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J. Clin. Oncol. 2007;25(11):1329-33.<br><br></td></tr><td valign='top' style='width:25%;'><img src="images/5stars.png" width="100" height="30"><br><br></td></tr></table><table width='700px' class='noPrint'><tr><td valign='top' style='font-size:12px;width:75%;'><a href='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4119541/'><u>Mazzola E, Chipman J, Cheng SC, Parmigiani G. Recent BRCAPRO upgrades significantly improve calibration. Cancer Epidemiology and Prevention Biomarkers. 2014 Aug 1;23(8):1689-95.</u><br><br></td><td valign='top' style='width:25%;'><img src="images/4stars.png" width="100" height="30"><br><br></td></tr></table><table width='700px' class='noScreen'><tr><td valign='top' style='font-size:12px;width:75%;'>Mazzola E, Chipman J, Cheng SC, Parmigiani G. Recent BRCAPRO upgrades significantly improve calibration. Cancer Epidemiology and Prevention Biomarkers. 2014 Aug 1;23(8):1689-95.<br><br></td></tr><td valign='top' style='width:25%;'><img src="images/4stars.png" width="100" height="30"><br><br></td></tr></table><table width='700px' class='noPrint'><tr><td valign='top' style='font-size:12px;width:75%;'><a href='https://www.ncbi.nlm.nih.gov/pubmed/28632866'><u>Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips KA, Mooij TM, Roos-Blom MJ, Jervis S, van Leeuwen FE, Milne RL, Andrieu N, Goldgar DE, Terry MB, Rookus MA, Easton DF, Antoniou AC, BRCA1 and BRCA2 Cohort Consortium, McGuffog L, Evans DG, Barrowdale D, Frost D, Adlard J, Ong KR, Izatt L, Tischkowitz M, Eeles R, Davidson R, Hodgson S, Ellis S, Nogues C, Lasset C, Stoppa-Lyonnet D, Fricker JP, Faivre L, Berthet P, Hooning MJ, van der Kolk LE, Kets CM, Adank MA, John EM, Chung WK, Andrulis IL, Southey M, Daly MB, Buys SS, Osorio A, Engel C, Kast K, Schmutzler RK, Caldes T, Jakubowska A, Simard J, Friedlander ML, McLachlan SA, Machackova E, Foretova L, Tan YY, Singer CF, Olah E, Gerdes AM, Arver B, Olsson H. Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. JAMA. 2017;317(23):2402-2416.</u><br><br></td><td valign='top' style='width:25%;'><img src="images/4stars.png" width="100" height="30"><br><br></td></tr></table><table width='700px' class='noScreen'><tr><td valign='top' style='font-size:12px;width:75%;'>Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips KA, Mooij TM, Roos-Blom MJ, Jervis S, van Leeuwen FE, Milne RL, Andrieu N, Goldgar DE, Terry MB, Rookus MA, Easton DF, Antoniou AC, BRCA1 and BRCA2 Cohort Consortium, McGuffog L, Evans DG, Barrowdale D, Frost D, Adlard J, Ong KR, Izatt L, Tischkowitz M, Eeles R, Davidson R, Hodgson S, Ellis S, Nogues C, Lasset C, Stoppa-Lyonnet D, Fricker JP, Faivre L, Berthet P, Hooning MJ, van der Kolk LE, Kets CM, Adank MA, John EM, Chung WK, Andrulis IL, Southey M, Daly MB, Buys SS, Osorio A, Engel C, Kast K, Schmutzler RK, Caldes T, Jakubowska A, Simard J, Friedlander ML, McLachlan SA, Machackova E, Foretova L, Tan YY, Singer CF, Olah E, Gerdes AM, Arver B, Olsson H. Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. JAMA. 2017;317(23):2402-2416.<br><br></td></tr><td valign='top' style='width:25%;'><img src="images/4stars.png" width="100" height="30"><br><br></td></tr></table><table width='700px' class='noPrint'><tr><td valign='top' style='font-size:12px;width:75%;'><a href='http://ascopubs.org/doi/abs/10.1200/PO.16.00066'><u>Kurian AW, Hughes E, Handorf EA, Gutin A, Allen B, Hartman A, Hall MJ. Breast and Ovarian Cancer Penetrance Estimates Derived From Germline Multiple-Gene Sequencing Results in Women. JCO Precision Oncology. 2017;(1):1-12</u><br><br></td><td valign='top' style='width:25%;'><img src="images/4stars.png" width="100" height="30"><br><br></td></tr></table><table width='700px' class='noScreen'><tr><td valign='top' style='font-size:12px;width:75%;'>Kurian AW, Hughes E, Handorf EA, Gutin A, Allen B, Hartman A, Hall MJ. Breast and Ovarian Cancer Penetrance Estimates Derived From Germline Multiple-Gene Sequencing Results in Women. JCO Precision Oncology. 2017;(1):1-12<br><br></td></tr><td valign='top' style='width:25%;'><img src="images/4stars.png" width="100" height="30"><br><br></td></tr></table><table width='700px' class='noPrint'><tr><td valign='top' style='font-size:12px;width:75%;'><a href='https://www.ncbi.nlm.nih.gov/pubmed/28418444'><u>Couch FJ, Shimelis H, Hu C, Hart SN, Polley EC, Na J, Hallberg E, Moore R, Thomas A, Lilyquist J, Feng B, McFarland R, Pesaran T, Huether R, LaDuca H, Chao EC, Goldgar DE, Dolinsky JS. Associations Between Cancer Predisposition Testing Panel Genes and Breast Cancer. JAMA Oncol. 2017;():.</u><br><br></td><td valign='top' style='width:25%;'><img src="images/4stars.png" width="100" height="30"><br><br></td></tr></table><table width='700px' class='noScreen'><tr><td valign='top' style='font-size:12px;width:75%;'>Couch FJ, Shimelis H, Hu C, Hart SN, Polley EC, Na J, Hallberg E, Moore R, Thomas A, Lilyquist J, Feng B, McFarland R, Pesaran T, Huether R, LaDuca H, Chao EC, Goldgar DE, Dolinsky JS. Associations Between Cancer Predisposition Testing Panel Genes and Breast Cancer. JAMA Oncol. 2017;():.<br><br></td></tr><td valign='top' style='width:25%;'><img src="images/4stars.png" width="100" height="30"><br><br></td></tr></table><table width='700px' class='noPrint'><tr><td valign='top' style='font-size:12px;width:75%;'><a href='https://www.ncbi.nlm.nih.gov/pubmed/24516540'><u>Caleca L, Putignano AL, Colombo M, Congregati C, Sarkar M, Magliery TJ, Ripamonti CB, Foglia C, Peissel B, Zaffaroni D, Manoukian S, Tondini C, Barile M, Pensotti V, Bernard L, Papi L, Radice P. Characterization of an Italian founder mutation in the RING-finger domain of BRCA1. PLoS ONE. 2014;9(2):e86924.</u><br><br></td><td valign='top' style='width:25%;'><img src="images/2stars.png" width="100" height="30"><br><br></td></tr></table><table width='700px' class='noScreen'><tr><td valign='top' style='font-size:12px;width:75%;'>Caleca L, Putignano AL, Colombo M, Congregati C, Sarkar M, Magliery TJ, Ripamonti CB, Foglia C, Peissel B, Zaffaroni D, Manoukian S, Tondini C, Barile M, Pensotti V, Bernard L, Papi L, Radice P. Characterization of an Italian founder mutation in the RING-finger domain of BRCA1. PLoS ONE. 2014;9(2):e86924.<br><br></td></tr><td valign='top' style='width:25%;'><img src="images/2stars.png" width="100" height="30"><br><br></td></tr></table><table width='700px' class='noPrint'><tr><td valign='top' style='font-size:12px;width:75%;'><a href='https://www.ncbi.nlm.nih.gov/pubmed/24695549'><u>Christou CM, Hadjisavvas A, Kyratzi M, Flouri C, Neophytou I, Anastasiadou V, Loizidou MA, Kyriacou K. The BRCA1 variant p.Ser36Tyr abrogates BRCA1 protein function and potentially confers a moderate risk of breast cancer. PLoS ONE. 2014;9(4):e93400.</u><br><br></td><td valign='top' style='width:25%;'><img src="images/1stars.png" width="100" height="30"><br><br></td></tr></table><table width='700px' class='noScreen'><tr><td valign='top' style='font-size:12px;width:75%;'>Christou CM, Hadjisavvas A, Kyratzi M, Flouri C, Neophytou I, Anastasiadou V, Loizidou MA, Kyriacou K. The BRCA1 variant p.Ser36Tyr abrogates BRCA1 protein function and potentially confers a moderate risk of breast cancer. PLoS ONE. 2014;9(4):e93400.<br><br></td></tr><td valign='top' style='width:25%;'><img src="images/1stars.png" width="100" height="30"><br><br></td></tr></table><table width='700px' class='noPrint'><tr><td valign='top' style='font-size:12px;width:75%;'><a href='https://www.ncbi.nlm.nih.gov/pubmed/19863560'><u>Ghadirian P, Robidoux A, Zhang P, Royer R, Akbari M, Zhang S, Fafard E, Costa M, Martin G, Potvin C, Patocskai E, Larouche N, Younan R, Nassif E, Giroux S, Narod SA, Rousseau F, Foulkes WD. The contribution of founder mutations to early-onset breast cancer in French-Canadian women. Clin. Genet. 2009;76(5):421-6.</u><br><br></td><td valign='top' style='width:25%;'><img src="images/1stars.png" width="100" height="30"><br><br></td></tr></table><table width='700px' class='noScreen'><tr><td valign='top' style='font-size:12px;width:75%;'>Ghadirian P, Robidoux A, Zhang P, Royer R, Akbari M, Zhang S, Fafard E, Costa M, Martin G, Potvin C, Patocskai E, Larouche N, Younan R, Nassif E, Giroux S, Narod SA, Rousseau F, Foulkes WD. The contribution of founder mutations to early-onset breast cancer in French-Canadian women. Clin. Genet. 2009;76(5):421-6.<br><br></td></tr><td valign='top' style='width:25%;'><img src="images/1stars.png" width="100" height="30"><br><br></td></tr></table><table width='700px' class='noPrint'><tr><td valign='top' style='font-size:12px;width:75%;'><a href='https://www.ncbi.nlm.nih.gov/pubmed/16644204'><u>Lalloo F, Varley J, Moran A, Ellis D, O'dair L, Pharoah P, Antoniou A, Hartley R, Shenton A, Seal S, Bulman B, Howell A, Evans DG. BRCA1, BRCA2 and TP53 mutations in very early-onset breast cancer with associated risks to relatives. Eur. J. Cancer. 2006;42(8):1143-50.</u><br><br></td><td valign='top' style='width:25%;'><img src="images/1stars.png" width="100" height="30"><br><br></td></tr></table><table width='700px' class='noScreen'><tr><td valign='top' style='font-size:12px;width:75%;'>Lalloo F, Varley J, Moran A, Ellis D, O'dair L, Pharoah P, Antoniou A, Hartley R, Shenton A, Seal S, Bulman B, Howell A, Evans DG. BRCA1, BRCA2 and TP53 mutations in very early-onset breast cancer with associated risks to relatives. Eur. J. Cancer. 2006;42(8):1143-50.<br><br></td></tr><td valign='top' style='width:25%;'><img src="images/1stars.png" width="100" height="30"><br><br></td></tr></table><p style='font-size:16px;font-weight:600;'>Ovarian</p><table width='700px' class='noPrint'><tr><td valign='top' style='font-size:12px;width:75%;'><a href='https://www.ncbi.nlm.nih.gov/pubmed/17416853'><u>Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J. Clin. Oncol. 2007;25(11):1329-33.</u><br><br></td><td valign='top' style='width:25%;'><img src="images/5stars.png" width="100" height="30"><br><br></td></tr></table><table width='700px' class='noScreen'><tr><td valign='top' style='font-size:12px;width:75%;'>Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J. Clin. Oncol. 2007;25(11):1329-33.<br><br></td></tr><td valign='top' style='width:25%;'><img src="images/5stars.png" width="100" height="30"><br><br></td></tr></table><table width='700px' class='noPrint'><tr><td valign='top' style='font-size:12px;width:75%;'><a href='http://ascopubs.org/doi/abs/10.1200/PO.16.00066'><u>Kurian AW, Hughes E, Handorf EA, Gutin A, Allen B, Hartman A, Hall MJ. Breast and Ovarian Cancer Penetrance Estimates Derived From Germline Multiple-Gene Sequencing Results in Women. JCO Precision Oncology. 2017;(1):1-12</u><br><br></td><td valign='top' style='width:25%;'><img src="images/4stars.png" width="100" height="30"><br><br></td></tr></table><table width='700px' class='noScreen'><tr><td valign='top' style='font-size:12px;width:75%;'>Kurian AW, Hughes E, Handorf EA, Gutin A, Allen B, Hartman A, Hall MJ. Breast and Ovarian Cancer Penetrance Estimates Derived From Germline Multiple-Gene Sequencing Results in Women. JCO Precision Oncology. 2017;(1):1-12<br><br></td></tr><td valign='top' style='width:25%;'><img src="images/4stars.png" width="100" height="30"><br><br></td></tr></table><table width='700px' class='noPrint'><tr><td valign='top' style='font-size:12px;width:75%;'><a href='https://www.ncbi.nlm.nih.gov/pubmed/26720728'><u>Norquist BM, Harrell MI, Brady MF, Walsh T, Lee MK, Gulsuner S, Bernards SS, Casadei S, Yi Q, Burger RA, Chan JK, Davidson SA, Mannel RS, DiSilvestro PA, Lankes HA, Ramirez NC, King MC, Swisher EM, Birrer MJ. Inherited Mutations in Women With Ovarian Carcinoma. JAMA Oncol. 2016;2(4):482-90.</u><br><br></td><td valign='top' style='width:25%;'><img src="images/4stars.png" width="100" height="30"><br><br></td></tr></table><table width='700px' class='noScreen'><tr><td valign='top' style='font-size:12px;width:75%;'>Norquist BM, Harrell MI, Brady MF, Walsh T, Lee MK, Gulsuner S, Bernards SS, Casadei S, Yi Q, Burger RA, Chan JK, Davidson SA, Mannel RS, DiSilvestro PA, Lankes HA, Ramirez NC, King MC, Swisher EM, Birrer MJ. Inherited Mutations in Women With Ovarian Carcinoma. JAMA Oncol. 2016;2(4):482-90.<br><br></td></tr><td valign='top' style='width:25%;'><img src="images/4stars.png" width="100" height="30"><br><br></td></tr></table><table width='700px' class='noPrint'><tr><td valign='top' style='font-size:12px;width:75%;'><a href='https://www.ncbi.nlm.nih.gov/pubmed/28632866'><u>Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips KA, Mooij TM, Roos-Blom MJ, Jervis S, van Leeuwen FE, Milne RL, Andrieu N, Goldgar DE, Terry MB, Rookus MA, Easton DF, Antoniou AC, BRCA1 and BRCA2 Cohort Consortium, McGuffog L, Evans DG, Barrowdale D, Frost D, Adlard J, Ong KR, Izatt L, Tischkowitz M, Eeles R, Davidson R, Hodgson S, Ellis S, Nogues C, Lasset C, Stoppa-Lyonnet D, Fricker JP, Faivre L, Berthet P, Hooning MJ, van der Kolk LE, Kets CM, Adank MA, John EM, Chung WK, Andrulis IL, Southey M, Daly MB, Buys SS, Osorio A, Engel C, Kast K, Schmutzler RK, Caldes T, Jakubowska A, Simard J, Friedlander ML, McLachlan SA, Machackova E, Foretova L, Tan YY, Singer CF, Olah E, Gerdes AM, Arver B, Olsson H. Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. JAMA. 2017;317(23):2402-2416.</u><br><br></td><td valign='top' style='width:25%;'><img src="images/4stars.png" width="100" height="30"><br><br></td></tr></table><table width='700px' class='noScreen'><tr><td valign='top' style='font-size:12px;width:75%;'>Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips KA, Mooij TM, Roos-Blom MJ, Jervis S, van Leeuwen FE, Milne RL, Andrieu N, Goldgar DE, Terry MB, Rookus MA, Easton DF, Antoniou AC, BRCA1 and BRCA2 Cohort Consortium, McGuffog L, Evans DG, Barrowdale D, Frost D, Adlard J, Ong KR, Izatt L, Tischkowitz M, Eeles R, Davidson R, Hodgson S, Ellis S, Nogues C, Lasset C, Stoppa-Lyonnet D, Fricker JP, Faivre L, Berthet P, Hooning MJ, van der Kolk LE, Kets CM, Adank MA, John EM, Chung WK, Andrulis IL, Southey M, Daly MB, Buys SS, Osorio A, Engel C, Kast K, Schmutzler RK, Caldes T, Jakubowska A, Simard J, Friedlander ML, McLachlan SA, Machackova E, Foretova L, Tan YY, Singer CF, Olah E, Gerdes AM, Arver B, Olsson H. Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. JAMA. 2017;317(23):2402-2416.<br><br></td></tr><td valign='top' style='width:25%;'><img src="images/4stars.png" width="100" height="30"><br><br></td></tr></table><table width='700px' class='noPrint'><tr><td valign='top' style='font-size:12px;width:75%;'><a href='https://www.ncbi.nlm.nih.gov/pubmed/24516540'><u>Caleca L, Putignano AL, Colombo M, Congregati C, Sarkar M, Magliery TJ, Ripamonti CB, Foglia C, Peissel B, Zaffaroni D, Manoukian S, Tondini C, Barile M, Pensotti V, Bernard L, Papi L, Radice P. Characterization of an Italian founder mutation in the RING-finger domain of BRCA1. PLoS ONE. 2014;9(2):e86924.</u><br><br></td><td valign='top' style='width:25%;'><img src="images/2stars.png" width="100" height="30"><br><br></td></tr></table><table width='700px' class='noScreen'><tr><td valign='top' style='font-size:12px;width:75%;'>Caleca L, Putignano AL, Colombo M, Congregati C, Sarkar M, Magliery TJ, Ripamonti CB, Foglia C, Peissel B, Zaffaroni D, Manoukian S, Tondini C, Barile M, Pensotti V, Bernard L, Papi L, Radice P. Characterization of an Italian founder mutation in the RING-finger domain of BRCA1. PLoS ONE. 2014;9(2):e86924.<br><br></td></tr><td valign='top' style='width:25%;'><img src="images/2stars.png" width="100" height="30"><br><br></td></tr></table><table width='700px' class='noPrint'><tr><td valign='top' style='font-size:12px;width:75%;'><a href='https://www.ncbi.nlm.nih.gov/pubmed/16644204'><u>Lalloo F, Varley J, Moran A, Ellis D, O'dair L, Pharoah P, Antoniou A, Hartley R, Shenton A, Seal S, Bulman B, Howell A, Evans DG. BRCA1, BRCA2 and TP53 mutations in very early-onset breast cancer with associated risks to relatives. Eur. J. Cancer. 2006;42(8):1143-50.</u><br><br></td><td valign='top' style='width:25%;'><img src="images/1stars.png" width="100" height="30"><br><br></td></tr></table><table width='700px' class='noScreen'><tr><td valign='top' style='font-size:12px;width:75%;'>Lalloo F, Varley J, Moran A, Ellis D, O'dair L, Pharoah P, Antoniou A, Hartley R, Shenton A, Seal S, Bulman B, Howell A, Evans DG. BRCA1, BRCA2 and TP53 mutations in very early-onset breast cancer with associated risks to relatives. Eur. J. Cancer. 2006;42(8):1143-50.<br><br></td></tr><td valign='top' style='width:25%;'><img src="images/1stars.png" width="100" height="30"><br><br></td></tr></table><p style='font-size:16px;font-weight:600;'>Pancreatic</p><table width='700px' class='noPrint'><tr><td valign='top' style='font-size:12px;width:75%;'><a href='https://www.ncbi.nlm.nih.gov/pubmed/23456555'><u>Mocci E, Milne RL, MÃ©ndez-Villamil EY, Hopper JL, John EM, Andrulis IL, Chung WK, Daly M, Buys SS, Malats N, Goldgar DE. Risk of pancreatic cancer in breast cancer families from the breast cancer family registry. Cancer Epidemiol. Biomarkers Prev. 2013;22(5):803-11.</u><br><br></td><td valign='top' style='width:25%;'><img src="images/4stars.png" width="100" height="30"><br><br></td></tr></table><table width='700px' class='noScreen'><tr><td valign='top' style='font-size:12px;width:75%;'>Mocci E, Milne RL, MÃ©ndez-Villamil EY, Hopper JL, John EM, Andrulis IL, Chung WK, Daly M, Buys SS, Malats N, Goldgar DE. Risk of pancreatic cancer in breast cancer families from the breast cancer family registry. Cancer Epidemiol. Biomarkers Prev. 2013;22(5):803-11.<br><br></td></tr><td valign='top' style='width:25%;'><img src="images/4stars.png" width="100" height="30"><br><br></td></tr></table><table width='700px' class='noPrint'><tr><td valign='top' style='font-size:12px;width:75%;'><a href='https://www.ncbi.nlm.nih.gov/pubmed/22187320'><u>Moran A, O'Hara C, Khan S, Shack L, Woodward E, Maher ER, Lalloo F, Evans DG. Risk of cancer other than breast or ovarian in individuals with BRCA1 and BRCA2 mutations. Fam. Cancer. 2012;11(2):235-42.</u><br><br></td><td valign='top' style='width:25%;'><img src="images/4stars.png" width="100" height="30"><br><br></td></tr></table><table width='700px' class='noScreen'><tr><td valign='top' style='font-size:12px;width:75%;'>Moran A, O'Hara C, Khan S, Shack L, Woodward E, Maher ER, Lalloo F, Evans DG. Risk of cancer other than breast or ovarian in individuals with BRCA1 and BRCA2 mutations. Fam. Cancer. 2012;11(2):235-42.<br><br></td></tr><td valign='top' style='width:25%;'><img src="images/4stars.png" width="100" height="30"><br><br></td></tr></table><tr><td>&nbsp;</td></tr></table>		
		<table class="noPrint" width="700px">
		<tr><td>&nbsp;</td></tr>
		<tr><td style="font-size:14px;font-weight:600;text-align:center;">If you want more information about classification of a specific variant in the BRCA1 gene, you can search for the latest variant information at <a target="_blank" href="https://www.ncbi.nlm.nih.gov/clinvar/"><u>ClinVar</u></a>.</td></tr>
		<tr><td>&nbsp;</td></tr>
		<tr><td style="font-size:14px;font-weight:600;text-align:center;">The estimates on this website are based on extensive literature review identifying reliable studies on the cancer risk implications for each gene. We welcome any questions or comments to keep our website up-to-date. To post your suggestions, <a target="_blank" href="http://www.ask2me.org/comments.php"><u>click here</u></a>.</td></tr>
		<tr><td>&nbsp;</td></tr>
		<tr><td style="font-size:14px;font-weight:600;text-align:center;">Computations are provided by the Risk Web Service developed jointly by the <a target="_blank" href="http://www.massgeneral.org/research/researchlab.aspx?id=1434"><u>Hughes Lab</u></a> at the Massachusetts General Hospital and the <a target="_blank" href="http://bcb.dfci.harvard.edu/bayesmendel/"><u>Bayes Mendel Lab</u></a> at the Dana-Farber Cancer Institute.</td></tr>
		<tr><td>&nbsp;</td></tr>
		<tr><td style="font-size:14px;font-weight:600;text-align:center;">The use of this report is subject to the terms and conditions stated on <a href="https://www.ask2me.org/terms.php"><u>https://www.ask2me.org</u></a>.</td></tr>
	</table>
	<table class="noScreen" width="700px">
		<tr><td>&nbsp;</td></tr>
		<tr><td style="font-size:14px;font-weight:600;text-align:center;">If you want more information about classification of a specific variant in the BRCA1 gene, you can search for the latest variant information at <a target="_blank" href="https://www.ncbi.nlm.nih.gov/clinvar/"><u>ClinVar</u></a> or <a target="_blank" href="https://varsome.com"><u>Varsome</u></a>.</td></tr>
		<tr><td>&nbsp;</td></tr>
		<tr><td style="font-size:14px;font-weight:600;text-align:center;">The estimates on this website are based on extensive literature review identifying reliable studies on the cancer risk implications for each gene. We welcome any questions or comments to keep our website up-to-date.</td></tr>
		<tr><td>&nbsp;</td></tr>
		<tr><td style="font-size:14px;font-weight:600;text-align:center;">Computations are provided by the Risk Web Service developed jointly by the Hughes Lab at the Massachusetts General Hospital and the Bayes Mendel Lab at the Dana-Farber Cancer Institute.</td></tr>
		<tr><td>&nbsp;</td></tr>
		<tr><td style="font-size:14px;font-weight:600;text-align:center;">The use of this report is subject to the terms and conditions stated on <a href="https://www.ask2me.org/terms.php"><u>https://www.ask2me.org</u></a>.</td></tr>
	</table>	
    <!-- Page Footer-->
    <div class="noPrint">
		<div class="inset-left-50 inset-right-50 inset-xs-left-0 inset-xs-right-0 inset-lg-right-50">
			<p>&nbsp;</p>
			<center><button style="width:300px;" type="button" class="btn btn-block btn-primary" onclick="window.history.back();">Back</button></center>
		</div>
	</div>
    <p>&nbsp;</p>
    <table class="noPrint" style="width:700px">
        <tr>
        	<td width="75%"><a target="_blank" href="http://www.dana-farber.org/"><img width="150px" style="border: none;" src="images/dfci-logo.jpg" alt="Dana-Farber Cancer Institute" /></a>&nbsp;&nbsp;&nbsp;<a target="_blank" href="http://www.massgeneral.org"><img style="border: none;" src="images/mgh-logo.png" width="150px" alt="Massachusetts General Hospital" /></a>&nbsp;&nbsp;&nbsp;<a style="border: none;" target="_blank" href="http://www.myjimmyfundpage.org/give/ask2me"><img style="border: none;" src="images/givingpages.jpg" width="200px" alt="Jimmy Fund/Dana-Farer Cancer Institute Giving" /></a></td>
        	<td width="25%" style="font-size: 10px;text-align:right;">&copy; 2016 &bullet; <a href="terms.php"><u>Terms and Conditions</u>.</a> <span style="font-size: 6pt;">Platform: prod</span><br><span style="font-size: 9pt;">Version 1.00</span><td>
        </tr>
    </table>
    <table class="noScreen" style="width:700px">
        <tr>
        	<td width="50%"><img style="border: none;" src="images/dfci-logo.jpg" alt="Dana-Farber Cancer Institute" />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<img style="border: none;" src="images/mgh-logo.png" alt="Massachusetts General Hospital" /></td>
        	<td width="50%" style="font-size: 12px;text-align:right;">&copy; 2016-2017 • <br><span style="font-size: 11pt;">Version 1.00</span><td>
        </tr>
    </table>    
    </div>
</body>
</html>